The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Regulatory News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal

24 Feb 2021 07:01

RNS Number : 1109Q
Reckitt Benckiser Group PLC
24 February 2021
 

RB Announces the Proposed Sale of Scholl to Yellow Wood Partners

24 February 2021 - Slough, UK - Reckitt Benckiser Group plc ("RB") is pleased to announce a transaction for the sale of Scholl (the "Sale") to Yellow Wood Partners ("Yellow Wood"). The proposed Sale is a step forward in RB's plan to bring greater focus to its portfolio.

Laxman Narasimhan, Chief Executive Officer of RB, said:

"Under RB's ownership, Scholl strengthened its position as the number one footcare brand worldwide and established a new global category. Scholl is now ready for its next exciting phase of growth and, building on the strong foundations established over the last 10 years, we are confident it would reach even greater heights under Yellow Wood's ownership, with the unique opportunity of reuniting Scholl with Dr. Scholl's."

Dana Schmaltz, Partner at Yellow Wood, said:

"We are excited to reunite the Scholl brand globally to continue the legacy and heritage of the century old Dr. Scholl's brand. Scholl is a strong business which has been outperforming the market, gaining market share across its key regions. The company has an excellent product portfolio, a great customer base, and leading positions in the markets it serves. This is a significant investment in Scholl's continued growth and as a combined global company we will be better positioned to take advantage of market opportunities and build the business in partnership with management and employees."

The proposed transaction between RB and Yellow Wood is subject to consultation with RB's works council in France which RB will now initiate. Subject to that consultation and the satisfaction of relevant closing conditions, it is expected that completion of the Sale would occur by Q3 2021.

- ENDS -

For further information, please contact:

RB

John Dawson +44 (0)7408 809474

SVP, Investor Relations

Patty O'Hayer +44 (0)7825 755688

Director, External Relations and Government Affairs

Finsbury Glover Hering +44 (0)7768 943171

Faeth Birch

About Scholl

Scholl is a leading global footcare brand that produces a wide range of skin care products, insoles and treatment solutions for targeted foot conditions. The brand was founded in 1906 by William Scholl in Chicago, US and has a long history of innovation and category leadership. RB acquired the brand as part of its acquisition of SSL International in 2010. The proposed Sale also includes RB's Amopé, Krack and Eulactol footcare brands.

 

About RB

RB is driven by its purpose to protect, heal and nurture in a relentless pursuit of a cleaner, healthier world. We fight to make access to the highest-quality hygiene, wellness and nourishment a right, not a privilege, for everyone. RB is proud to have a stable of trusted household brands found in households in more than 190 countries. These include Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite, Air Wick and more. 20 million RB products a day are bought by consumers globally. RB's passion to put consumers and people first, to seek out new opportunities, to strive for excellence in all that we do, and to build shared success with all our partners, while doing the right thing, always is what guides the work of our 40,000+ diverse and talented colleagues worldwide. For more information visit www.rb.com

RB is the trading name of the Reckitt Benckiser group of companies.

 

Further Information

Centerview Partners UK LLP ("Centerview") and Citigroup Global Markets Limited ("Citi") acted as financial advisers to RB on the transaction.

 

Centerview, which is regulated in the United Kingdom by the Financial Conduct Authority ("FCA"), is acting as financial adviser exclusively for RB and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than RB for providing the protections afforded to clients of Centerview nor for providing advice in relation to any matter referred to herein.

 

Citi, which is authorised by the Prudential Regulation Authority ("PRA") and regulated in the UK by the FCA and the PRA, is acting as financial adviser exclusively for RB and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than RB for providing the protections afforded to clients of Citi nor for providing advice in relation to any matter referred to herein.

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISPPUQPPUPGPGW
Date   Source Headline
22nd Jan 20154:55 pmRNSShare repurchase
21st Jan 20155:19 pmRNSShare repurchase
20th Jan 20154:51 pmRNSShare repurchase
19th Jan 20155:06 pmRNSShare repurchase
16th Jan 20154:46 pmRNSShare repurchase
15th Jan 20155:18 pmRNSShare repurchase
14th Jan 20155:00 pmRNSShare repurchase
13th Jan 20154:56 pmRNSShare repurchase
12th Jan 20155:00 pmRNSShare repurchase
9th Jan 20154:53 pmRNSShare repurchase
8th Jan 20154:53 pmRNSShare repurchase
7th Jan 20154:51 pmRNSShare repurchase
6th Jan 20155:46 pmRNSShare repurchase
6th Jan 20154:00 pmRNSDirector/PDMR Shareholding
5th Jan 20155:13 pmRNSShare repurchase
2nd Jan 20155:48 pmRNSShare repurchase
31st Dec 201411:15 amRNSTotal Voting Rights
23rd Dec 20149:45 amRNSDirector Declaration
23rd Dec 20148:00 amRNSRB completes demerger of Indivior
18th Dec 201410:39 amRNSFrench Competition Fine
12th Dec 20146:21 pmRNSDirector/PDMR Shareholding
12th Dec 20145:00 pmRNSShare Repurchase Programme
10th Dec 20141:14 pmRNSChairman's proxy votes for GM on 11 December 2014
4th Dec 20145:45 pmRNSShare repurchase
4th Dec 201412:40 pmRNSDirector/PDMR Shareholding
3rd Dec 20145:26 pmRNSShare repurchase
2nd Dec 20145:18 pmRNSShare repurchase
2nd Dec 20145:01 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:58 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:53 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:50 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:47 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:40 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:37 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:34 pmRNSDirector/PDMR Shareholding
1st Dec 20145:13 pmRNSShare repurchase
1st Dec 20142:06 pmRNSExecutive Committee Changes
28th Nov 20145:20 pmRNSTotal Voting Rights
28th Nov 20145:14 pmRNSShare repurchase
27th Nov 20144:58 pmRNSShare repurchase
26th Nov 20145:19 pmRNSShare repurchase
25th Nov 20145:13 pmRNSShare repurchase
24th Nov 20145:20 pmRNSShare repurchase
21st Nov 20145:11 pmRNSShare repurchase
20th Nov 20144:51 pmRNSShare repurchase
19th Nov 20144:56 pmRNSShare repurchase
18th Nov 20145:05 pmRNSShare repurchase
17th Nov 20144:55 pmRNSShare repurchase
17th Nov 20144:36 pmRNSCircular re Demerger and Notice of General Meeting
17th Nov 20147:00 amRNSProposed Demerger of the RB Pharma business

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.